Alexandria Real Estate Equities has contributed to a $76m round for KSQ, which is developing genomics-focused oncology and immunology drugs.

AbbVie Ventures has participated in a $20m round that will support nanotechnology drug developer Exicure's reverse merger with a shell company.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.

Integra, set up by Yissum to invest in life science spinouts from Hebrew University of Jerusalem, has secured an initial tranche led by Temasek.

Evotec has injected $17.7m into Exscientia, becoming the first strategic shareholder in the drug discovery spinout based on research at University of Dundee.

The pharmaceutical company has invested in healthcare analytics software provider Caresyntax through its corporate venturing subsidiary.